GUELI, ANGELA
GUELI, ANGELA
BIOTECNOLOGIE MOLECOLARI E SCIENZE PER LA SALUTE
Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: a case repor
2013-01-01 Gueli A; Gottardi D; Hu H; Ricca I; De Crescenzo A; Tarella C.
Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin's Lymphoma: Correlation with Long-Term Survival
2014-01-01 Tarella C; Gueli A; Delaini F; Rossi A; Barbui AM; Gritti G; Boschini C; Caracciolo D; Bruna R; Ruella M; Gottardi D; Passera R; Rambaldi A.
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma
2011-01-01 Tarella C; Passera R; Magni M; Benedetti F; Rossi A; Gueli A; Patti C; Parvis G; Ciceri F; Gallamini A; Cortelazzo S; Zoli V; Corradini P; Carobbio A; Mulé A; Bosa M; Barbui A; Di Nicola M; Sorio M; Caracciolo D; Gianni AM; Rambaldi A
Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma.
2013-01-01 Ferrero S; Monitillo L; Mantoan B; Barbero D; Genuardi E; Barbiero S; Bernocco E; Caracciolo D; Ruella M; Drandi D; Zanni M; Renna F; Lobetti Bodoni C; Gueli A; Passera R; Musto P; Boccadoro M; Tarella C; Ladetto M.
The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy
2013-01-01 Rambaldi A; Boschini C; Gritti G; Delaini F; Oldani E; Rossi A; Barbui AM; Caracciolo D; Ladetto M; Gueli A; De Crescenzo A; Passera R; Devizzi L; Patti C; Gianni AM; Tarella C.
Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report.
2012-01-01 Sivera P; Ruella M; Gueli A; Hu H; Wade M; Tarella C.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Efficacy of rituximab-bendamustine in cold agglutinin haemolytic anaemia refractory to previous chemo-immunotherapy: a case repor | 2013 | Gueli A; Gottardi D; Hu H; Ricca I; De Crescenzo A; Tarella C. | |
| Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin's Lymphoma: Correlation with Long-Term Survival | 2014 | Tarella C; Gueli A; Delaini F; Rossi A; Barbui AM; Gritti G; Boschini C; Caracciolo D; Bruna R; Ruella M; Gottardi D; Passera R; Rambaldi A. | |
| Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma | 2011 | Tarella C; Passera R; Magni M; Benedetti F; Rossi A; Gueli A; Patti C; Parvis G; Ciceri F; Gallamini A; Cortelazzo S; Zoli V; Corradini P; Carobbio A; Mulé A; Bosa M; Barbui A; Di Nicola M; Sorio M; Caracciolo D; Gianni AM; Rambaldi A | |
| Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. | 2013 | Ferrero S; Monitillo L; Mantoan B; Barbero D; Genuardi E; Barbiero S; Bernocco E; Caracciolo D; Ruella M; Drandi D; Zanni M; Renna F; Lobetti Bodoni C; Gueli A; Passera R; Musto P; Boccadoro M; Tarella C; Ladetto M. | |
| The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy | 2013 | Rambaldi A; Boschini C; Gritti G; Delaini F; Oldani E; Rossi A; Barbui AM; Caracciolo D; Ladetto M; Gueli A; De Crescenzo A; Passera R; Devizzi L; Patti C; Gianni AM; Tarella C. | |
| Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report. | 2012 | Sivera P; Ruella M; Gueli A; Hu H; Wade M; Tarella C. |